IDEXX Laboratories Financials

IDXX Stock

USD 450.90 0.20 0.0444%

Net Income Per Employee is likely to drop to about 50.6 K in 2023. Revenue Per Employee is likely to drop to about 273.1 K in 2023.

With this module, you can analyze IDEXX financials for your investing period. You should be able to track the changes in IDEXX Laboratories individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

IDEXX Most Recent Estimates

Quarterly Earnings Growth

0.123

EPS Estimate Next Quarter

2.5

Diluted Eps

8.23

EPS Estimate Current Year

9.69

EPS Estimate Next Year

11.07

Understanding current and past IDEXX Laboratories Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of IDEXX Laboratories' financial statements are interrelated, with each one affecting the others. For example, an increase in IDEXX Laboratories' assets may result in an increase in income on the income statement.

The financial analysis of IDEXX Laboratories is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for IDEXX Laboratories includes many different criteria found on its balance sheet. For example, investors should never minimize IDEXX Laboratories' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor IDEXX Laboratories' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in IDEXX Laboratories.

Cash and Equivalents

141.62 Million

Evaluating IDEXX Laboratories' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of IDEXX Laboratories' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the IDEXX Laboratories' relative financial performance

Chance Of Distress

Less than 1

100

IDEXX Laboratories has less than 1 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for IDEXX Laboratories stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.

Please note, IDEXX Laboratories' odds of distress score SHOULD NOT be confused with the real chance of IDEXX Laboratories filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as IDEXX is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include IDEXX Laboratories' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

The data published in IDEXX Laboratories' official financial statements usually reflect IDEXX Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of IDEXX Laboratories. For example, before you start analyzing numbers published by IDEXX accountants, it's critical to develop an understanding of what IDEXX Laboratories' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.

Please note, the presentation of IDEXX Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, IDEXX Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Please utilize our Beneish M Score to check the likelihood of IDEXX Laboratories' management manipulating its earnings.

IDEXX Laboratories Company Summary

IDEXX Laboratories competes with Mednax, Laboratory, Cigna Corp, Doximity, and Guardant Health. IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. Idexx Laboratories operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 10000 people.

Specialization	Health Care, Health Care Equipment & Services
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
CIK Number	0000874716
ISIN	US45168D1046
CUSIP	45168D104
Region	North America
Location	Maine; U.S.A
Business Address	One IDEXX Drive,
Sector	Health Care Equipment & Supplies
Industry	Health Care
Benchmark	NYSE Composite
Website	www.idexx.com
Phone	207 556 0300
Currency	USD - US Dollar

You should never invest in IDEXX Laboratories without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of IDEXX Stock, because this is throwing your money away. Analyzing the key information contained in IDEXX Laboratories' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

IDEXX Laboratories Key Financial Ratios

Generally speaking, IDEXX Laboratories' financial ratios allow both analysts and investors to convert raw data from IDEXX Laboratories' financial statements into concise, actionable information that can be used to evaluate the performance of IDEXX Laboratories over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that IDEXX Laboratories reports annually and quarterly.

	Return On Asset	0.22 %
	Profit Margin	0.20 %
	Operating Margin	0.27 %

More Fundamentals

IDEXX Laboratories Key Balance Sheet Accounts

	2018	2019	2020	2021	2022	2023 (projected)
Inventories	173.3 M	195.02 M	209.87 M	269.03 M	367.82 M	396.86 M
Receivables	248.85 M	269.31 M	331.43 M	368.35 M	400.62 M	432.25 M
Accounts Payable	69.53 M	72.17 M	74.56 M	116.14 M	110.22 M	118.92 M
Total Assets	1.54 B	1.83 B	2.29 B	2.44 B	2.75 B	2.46 B
Current Assets	654.17 M	679.64 M	1.06 B	955.65 M	1.1 B	1.06 B
Assets Non Current	883.18 M	1.15 B	1.23 B	1.48 B	1.65 B	1.4 B
Cash and Equivalents	123.79 M	90.33 M	383.93 M	144.45 M	112.55 M	141.62 M
Total Debt	1 B	1.06 B	985.52 M	1.01 B	1.45 B	1.32 B
Debt Current	398.94 M	288.76 M	49.99 M	148.5 M	653.98 M	705.61 M
Debt Non Current	601.35 M	766.38 M	935.53 M	862.58 M	795.63 M	748.2 M
Deferred Revenue	101.99 M	90.2 M	88.73 M	81.21 M	68.8 M	74.89 M
Inventory	173.3 M	195.02 M	209.87 M	269.03 M	367.82 M	307.33 M
Total Liabilities	1.55 B	1.65 B	1.66 B	1.75 B	2.14 B	1.98 B
Current Liabilities	770.44 M	725.34 M	582.76 M	763.58 M	1.24 B	1.1 B
Tax Liabilities	29.27 M	33.02 M	11.71 M	8.94 M	8.15 M	8.36 M

IDEXX Laboratories Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what IDEXX Laboratories' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.

	2018	2019	2020	2021	2022	2023 (projected)
Direct Expenses	971.7 M	1.04 B	1.14 B	1.33 B	1.36 B	1.08 B
Consolidated Income	377.05 M	427.79 M	582.13 M	744.84 M	679.09 M	569.86 M
Cost of Revenue	971.7 M	1.04 B	1.14 B	1.33 B	1.36 B	1.25 B
Gross Profit	1.24 B	1.37 B	1.57 B	1.89 B	2 B	1.76 B
Interest Expense	34.74 M	31.05 M	33.12 M	29.81 M	39.86 M	36.33 M
Net Income	377.03 M	427.72 M	581.78 M	744.85 M	679.09 M	569.82 M
Operating Expenses	750.21 M	812.7 M	876.52 M	957.4 M	1.11 B	996.83 M
Operating Income	491.33 M	552.85 M	694.52 M	932.03 M	898.76 M	758.42 M
Revenues	2.21 B	2.41 B	2.71 B	3.22 B	3.37 B	3 B
Income Tax Expense	80.69 M	94.43 M	79.85 M	157.81 M	180.88 M	153.87 M

IDEXX Laboratories Key Cash Accounts

Cash flow analysis captures how much money flows into and out of IDEXX Laboratories. It measures of how well IDEXX is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money IDEXX Laboratories brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money IDEXX had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what IDEXX Laboratories has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.

	2018	2019	2020	2021	2022	2023 (projected)
Capital Expenditure	(115.75 M)	(154.97 M)	(107.63 M)	(119.55 M)	(158.84 M)	(163.02 M)
Depreciation Amortization and Accretion	83.18 M	88.01 M	96 M	104.6 M	111.9 M	105.2 M
Net Cash Flow or Change in Cash and Cash Equivalents	(63.88 M)	(33.47 M)	293.6 M	(239.47 M)	(31.91 M)	(32.75 M)
Net Cash Flow Business Acquisitions and Disposals	(29.68 M)	(50.56 M)	(1.5 M)	(173.42 M)	(11.51 M)	(12.42 M)
Issuance Purchase of Equity Shares	(331.12 M)	(265.55 M)	(131.49 M)	(700.21 M)	(783.96 M)	(804.59 M)
Issuance Repayment of Debt Securities	(256.04 M)	(10.43 M)	(94.65 M)	20.85 M	430.06 M	464.02 M
Net Cash Flow from Financing	(597.8 M)	(286.41 M)	(248.42 M)	(697.41 M)	(370.94 M)	(400.22 M)
Net Cash Flow from Investing	138.6 M	(205.53 M)	(109.38 M)	(292.97 M)	(195.35 M)	(210.77 M)
Net Cash Flow Investment Acquisitions and Disposals	(47.41 M)	284.04 M	(250 K)	(25 M)	(28.75 M)	(29.51 M)
Net Cash Flow from Operations	400.08 M	459.16 M	648.06 M	755.55 M	542.98 M	519.68 M
Effect of Exchange Rate Changes on Cash	(4.77 M)	(689 K)	3.33 M	(4.64 M)	(8.61 M)	(8.83 M)
Share Based Compensation	25.16 M	39.28 M	30.95 M	37.76 M	49.77 M	53.7 M

IDEXX Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining IDEXX Laboratories's current stock value. Our valuation model uses many indicators to compare IDEXX Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IDEXX Laboratories competition to find correlations between indicators driving IDEXX Laboratories's intrinsic value. More Info.

IDEXX Laboratories is currently regarded as number one stock in price to book category among related companies. It is rated second overall in current liabilities category among related companies creating about 11,451,115 of Current Liabilities per Price to Book. IDEXX Laboratories Current Liabilities is fairly stable at the moment as compared to the past year. IDEXX Laboratories reported Current Liabilities of 1.24 Billion in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value IDEXX Laboratories by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for IDEXX Laboratories' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IDEXX Laboratories' earnings, one of the primary drivers of an investment's value.

IDEXX Laboratories Systematic Risk

IDEXX Laboratories' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. IDEXX Laboratories volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.

The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on IDEXX Laboratories correlated with the market. If Beta is less than 0 IDEXX Laboratories generally moves in the opposite direction as compared to the market. If IDEXX Laboratories Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one IDEXX Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of IDEXX Laboratories is generally in the same direction as the market. If Beta > 1 IDEXX Laboratories moves generally in the same direction as, but more than the movement of the benchmark.

About IDEXX Laboratories Financials

What exactly are IDEXX Laboratories Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include IDEXX Laboratories' income statement, its balance sheet, and the statement of cash flows. Potential IDEXX Laboratories investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although IDEXX Laboratories investors may use each financial statement separately, they are all related. The changes in IDEXX Laboratories's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on IDEXX Laboratories's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze IDEXX Laboratories Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as IDEXX Laboratories is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of IDEXX has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

In summary, you can determine if IDEXX Laboratories' financials are consistent with your investment objective using the following steps:

Review IDEXX Laboratories' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand IDEXX Laboratories' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare IDEXX Laboratories' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if IDEXX Laboratories' stock is overvalued or undervalued.

Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

IDEXX Laboratories Thematic Clasifications

IDEXX Laboratories is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions

Healthcare

View

This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

IDEXX Laboratories June 9, 2023 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of IDEXX Laboratories help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of IDEXX Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of IDEXX Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing IDEXX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build IDEXX Laboratories's daily price indicators and compare them against related drivers.

	Information Ratio	(0.035355)
	Maximum Drawdown	9.22
	Value At Risk	(4.05)
	Potential Upside	2.45

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for IDEXX Stock analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Money Managers Screen money managers from public funds and ETFs managed around the world
	CEO Directory Screen CEOs from public companies around the world
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.123

Earnings Share

8.23

Revenue Per Share

41.204

Quarterly Revenue Growth

0.076

Return On Assets

0.2154

The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

IDEXX Laboratories Financials

IDEXX Most Recent Estimates

Cash and Equivalents

141.62 Million

Chance Of Distress

Less than 1

IDEXX Laboratories Company Summary

IDEXX Laboratories Key Financial Ratios

IDEXX Laboratories Key Balance Sheet Accounts

IDEXX Laboratories Key Income Statement Accounts

IDEXX Laboratories Key Cash Accounts

IDEXX Financial Ratios Relationships

IDEXX Laboratories Systematic Risk

About IDEXX Laboratories Financials

Steps to analyze IDEXX Laboratories Financials for Investing

IDEXX Laboratories Thematic Clasifications

IDEXX Laboratories June 9, 2023 Opportunity Range

Complementary Tools for IDEXX Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY